UPDATE 1-Swiss aim to re-open economy, donate AstraZeneca COVID-19 shots

(Adds comment from health minister)

By John Miller

ZURICH, May 12 (Reuters) - Switzerland aims to expand its
economic re-opening and may donate millions of AstraZeneca
COVID-19 vaccine doses to developing countries as the
Alpine nation grows increasingly confident it is beating back
the pandemic.

Health Minister Alain Berset on Wednesday said the country
may give 3 million of 5.4 million AstraZeneca doses it has
reserved to the COVAX vaccine sharing programme. Switzerland has
enough mRNA shots from producers including Pfizer and
Moderna to cover 2021 and 2022, Berset said.

The government announced plans starting May 31 to re-open
indoor dining in restaurants, increase attendance at public
events and ease work-from-home requirements as infections,
hospitalisations and deaths have fallen.

A final decision is due on May 26.

AstraZeneca's shot, restricted in some countries or limited
to certain age groups after links to very rare blood clots, has
yet to be approved in Switzerland as the Swiss regulator seeks
more data.

"If it is approved, then only a limited number would be
deployed in Switzerland," Berset told a news conference in Bern.

"We looked at it today, and the Interior Ministry has been
tasked with making necessary inquiries about how we would donate
3 million doses available to COVAX."

So far, Switzerland has ordered more than 40 million vaccine
doses, including 13.5 million in 2021 and 7 million in 2022 from
Moderna, 6 million from Pfizer and its German partner BionTech
, 5 million from CureVac and 6 million from
Novavax.

Berset said mRNA vaccines -- from Moderna and Pfizer, as
well as CureVac's yet-to-be-approved shot -- form the backbone
of Switzerland's strategy for initial shots and future refresher
jabs, seen as likely as the coronavirus mutates.

Berset said people should continue to stick to social
distancing, mask wearing, and getting COVID-19 vaccines. About a
quarter of the 8.6 million population has got jabs so far.
(Reporting by John Miller, editing by John Revill and Michael
Shields)